Efficacy and safety of programmed cell death receptor 1 inhibition-based regimens in patients with pediatric malignancies: the real-world study in China

BACKGROUND: Programmed death receptor 1 (PD-1) inhibition has shown durable response and mild adverse events (AEs) in adult malignancies. However, data on the clinical activity of PD-1 inhibition in pediatric patients are lacking. We comprehensively assessed the efficacy and safety of PD-1 inhibitor...

Descripción completa

Detalles Bibliográficos
Autores principales: Hong, Ye, Song, Mengjia, Lan, Yingxia, Wang, Juan, Lu, Suying, Zhang, Yu, Zhu, Jia, Sun, Feifei, Huang, Junting, Liu, Juan, Xu, Jiaqian, Wu, Yanpeng, Guo, Haixia, Cai, Ruiqing, Zhen, Zijun, Que, Yi, Zhang, Yizhuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10288191/
https://www.ncbi.nlm.nih.gov/pubmed/37359533
http://dx.doi.org/10.3389/fimmu.2023.1182751

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10288191/
https://www.ncbi.nlm.nih.gov/pubmed/37359533
http://dx.doi.org/10.3389/fimmu.2023.1182751

Ejemplares similares